Zedira's MTG-Handbook

Microbial transglutaminase (MTG) is an enzyme originally produced by Streptomyces species. MTG catalyzes cross-linking of proteins in the absence of calcium. In simple words: MTG is a biological glue. While its physiological role is still not fully understood, MTG received major attraction by the industry for its protein cross-linking activity. It is applied in the production processes of meat, sausage, dairy, bakery, and pasta products to improve food properties.

Moreover, MTG cannot only cross-link proteins, but it can also incorporate primary amines to proteins in a covalent, irreversible manner. This feature allows to link a whole bundle of labels to proteins, including biotin, fluorescent dyes, click chemistry substrates, and cytotoxins.

MTG attracted more and more interest, as developers of antibody drug conjugates realized its unique property to generate site specific and homogenous antibody drug conjugates (ADCs). Today, ADCs manufactured with MTG entered clinical trials.

Zedira’s MTG-Handbook shall provide an overview on this fascinating enzyme. We highly appreciate the blogs of renowned colleagues form the MTG community as part of the handbook. The 2nd edition of Zedira’s MTG-Handbook includes additional information on MTG’s characteristics useful for the everyday work in the lab: pH- and temperature profile, stability and more. In addition, a starting protocol for antibody conjugation is included.

Download your softcopy here!

Please feel free to contact us if you would like to receive your personal hard copy of our handbook: contact@zedira.com


  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.


  • imageSuccessful ISO9001:2015 recertification
  • Dr. Falk Pharma and Zedira announce start of the phase 2a proof of concept study of ZED1227 for the treatment of non-alcoholic fatty liver disease (NAFLD)
  • Zedira publication - Features of ZED1227: The First-In-Class Tissue Transglutaminase Inhibitor Undergoing Clinical Evaluation for the Treatment of Celiac Disease
  • Dr. Falk Pharma and Zedira announce start of the phase 2b real-life study of ZED1227 for the treatment of Celiac Disease
  • imageDr. Falk Pharma and Zedira announce successful completion of the phase 2a proof-of-concept study of ZED1227 for the treatment of Celiac Disease
  • imageDr. Falk Pharma und Zedira verkünden den erfolgreichen Abschluss der Phase 2a-Studie mit ZED1227 zur Behandlung von Zöliakie
  • imageReversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis


  • DZG Aktuell: „Aufruf zur Teilnahme an einer weiteren Wirksamkeitsstudie mit dem Studienmedikament ZED1227“
  • imageDesign of Oral FXIIIa Blockers as Safer Anticoagulants – Mission Impossible?
  • imageMicrobial transglutaminase (MTG) enables efficient and site-specific conjugation to native antibodies without the need of antibody engineering


  • 19th International Celiac Disease Symposium

    19.10.2022 - 22.10.2022
    Sorrento, Italy